Cellectis S.A. | TalkMarkets

Latest Posts

About This Stock More About This Stock

Biotech And Pharma Stocks Await Q1 Earnings But Gene Editing Stocks Sell-Off

Article By: Rod Raynovich

Monday, April 23, 2018 5:38 PM EDT

Biotech stocks held current levels but small caps and speculative stocks sold off with the XBI down 1%.

In this article: MRK, AMGN, NBIX, XBI, GWPH, BLUE, CLLS, PTLA, EDIT, AVXS, NTLA, CRSP

Read

Biotechs Bounce Off Bottom On Novartis Deal But Fade Later In The Day

Article By: Rod Raynovich

Monday, April 9, 2018 7:49 PM EDT

Normally this kind of M&A news would be an opportunity to load up on biotechs but technicals are still weak and crosscurrents from economic and macro news create a risk-off sentiment.

In this article: NVS, FBT, AGIO, AVXS Also: IBB, SGMO, XBI, BLUE, ONCE, CLLS, EDIT, NTLA, CRSP

Read

Juno, CAR-T Peers Rise After Report Of Potential Celgene Deal

Article By: The Fly

Wednesday, January 17, 2018 12:59 PM EDT

Shares of Juno Therapeutics are on the rise after the Wall Street Journal reported that the company is in talks to be acquired by Celgene.

In this article: JUNO Also: CELG, GILD, BLUE, CLLS, BLCM

Read

2018 Outlook – Biotech Bonanza: Biotech Stocks To Keep Shining

Article By: Tarun Chandra, CFA

Sunday, December 17, 2017 11:58 AM EDT

Biotech is not an easy sector to invest in - 95 percent of the oncology drugs that enter clinical trials fail. But that is no reason to ignore biotechs. We believe biotech stocks in 2018 will deliver double-digit returns of around 20%.

In this article: ALNY, ALXN, ABEO Also: ASH, ARNA, AMGN, BIIB, ANAB, SPPI, ZGNX, NKTR, EXAS, SAGE, HALO, SGMO, DVAX, INSM, XBI, JUNO, ESPR, LOXO, RVNC, LABD, LABU, BPMC, MRTX, NVS, CLLS, BLUE, BMY, INCY, CELG, GILD, VRTX, REGN

Read